We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Axela Licenses Beckman's Universal Linker Capture Technology

By Labmedica staff writers
Posted on 20 Dec 2006
Axela Biosensors Inc. (Toronto, Canada), and Beckman Coulter Inc. (Fullerton, CA, USA), have announced the signing of a nonexclusive licensing agreement that gives Axela rights to Beckman Coulter's patented A2 universal linker capture technology. The terms of the license were not disclosed. Axela will incorporate the technology into its dotLab Sensors, which will give scientists the unique ability to create user-defined multiplex biomarker panels.

Combining A2 universal linkers with the recently launched dotLab System allows scientists to create custom multiplex protein assays without the need for specialized pipetting or spotting techniques. Axela plans to use the technology in conjunction with its dotLab sensors to allow users to define their own biomarker panels and to use either the Axela library of pre-conjugated antibodies or their own reagents with universal linkers.

"The innovative Universal Linker approach will allow users to tag their own antibodies or draw from a library of existing markers to build combined assays with micromolar to picomolar sensitivity requirements,” explained Rocky Ganske, CEO of Axela Biosensors.

"Coupled with the dotLab System, this self-addressing DNA approach gives the translational scientist a simple and flexible method to perform multiplexed immunoassays, and has the potential to significantly transform the speed in which putative biomarkers can be validated.”

Axela Biosensors is commercializing products that accelerate the validation of protein biomarkers from discovery into routine clinical practice. The company has developed a proprietary breakthrough technology called diffractive optics technology (dot), which enables the real-time detection and quantitation of protein-binding events in complex media. Axela developed this technology into the dotLabSystem, a commercially available benchtop laboratory system that delivers simple, affordable, yet highly sensitive protein based assays. To leverage the opportunities that dot creates, Axela has assembled a management team with extensive experience in diagnostic and research product development and commercialization.

Beckman Coulter, Inc. manufactures biomedical testing instrument systems, tests, and supplies that simplify and automate laboratory processes.



Related Links:
Axela Biosensors
Beckman Coulter

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Lab Sample Rotator
H5600 Revolver

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests